GALR1 and Insulin resistance: Immune biomarkers such as PGE and the NLRP-3 inflammasome, oxidative stress pathways, GAL-GAL-R1, and metabolic pathways including insulin resistance and PAI1 are new drug targets to prevent and treat long COVID and its physio-affective symptoms.